Form 4: Vertex Pharmaceuticals EVP, COO Stuart A. Arbuckle Reports Stock Disposal

Stuart A. Arbuckle, EVP and COO of Vertex Pharmaceuticals, reported the disposal of 7,071 shares of common stock to cover tax obligations.

Summary

• On February 26, 2025, Stuart A. Arbuckle, the EVP and COO of Vertex Pharmaceuticals, disposed of 7,071 shares of common stock.
• The transaction was executed at a price of $479.61 per share.
• This disposal was likely to cover tax obligations related to vesting of stock or option exercise.
• Following the transaction, Arbuckle directly owns 62,935 shares of Vertex Pharmaceuticals common stock.
• He also indirectly owns 140 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: This is a neutral event. An executive sold shares, likely for tax purposes. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of insider transactions. This filing indicates that an executive disposed of shares, which could be for various reasons including tax obligations or portfolio diversification. It's a common occurrence and doesn't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The disposal of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact.

Key Dates